Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment - PubMed (original) (raw)
. 2005 Nov 1;104(9):1931-8.
doi: 10.1002/cncr.21418.
Affiliations
- PMID: 16178004
- DOI: 10.1002/cncr.21418
Free article
Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment
Didier P Blaise et al. Cancer. 2005.
Free article
Abstract
Background: Thirty-three patients (median age 52; range 26-60) with acute myeloblastic leukemia (AML) were included in a pilot study of allogeneic stem cell transplantation (Allo-SCT) following a reduced-intensity conditioning (RIC).
Methods: Patients achieving first complete remission (CR1) were selected for their high-risk clinical and/or leukemic features. All patients received two courses of consolidation chemotherapy including one high-dose cytarabine course. Among them, 13 patients in addition received a high-dose melphalan course followed by autologous SCT. Then, all patients received an RIC Allo-SCT combining fludarabine, busulfan, and antithymocyte globulin.
Results: All patients engrafted had cumulative incidences of Gluksberg System Grade 2 acute and chronic graft-versus-host-disease (GVHD) of 24 (9-39%) and 64 (48-80%), respectively. Three patients died from nonrelapse causes (NRD) (cumulative incidence: 9%, 95% confidence interval (CI): 0-19) and 6 relapsed (cumulative incidence: 18%, 95% CI: 5-31). With a median follow-up of 18 months (range 7-52) after Allo-SCT, 26 patients are alive, of whom 24 remained in CR1 for a 2-year overall survival and leukemia-free survival (LFS) probabilities of 79 (range 61-90%) and 76 (range 59-87%), respectively. In a 'landmark' analysis starting on Day 100, the occurrence of chronic GVHD was associated with a lower relapse rate (0% vs. 44%: P = 0.007) and improved outcome (LFS; 95% vs. 53%, P = 0.007; overall survival, 95% vs. 61%, P = 0.05).
Conclusions: We conclude that the sequential combination of intensive chemotherapy and allogeneic immunotherapy might offer relatively low NRD and leukemia relapse rates even in high-risk patients.
(c) 2005 American Cancer Society.
Similar articles
- Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR; German Cooperative Transplant Study Group. Kröger N, et al. Ann Hematol. 2003 Jun;82(6):336-42. doi: 10.1007/s00277-003-0654-9. Epub 2003 May 1. Ann Hematol. 2003. PMID: 12728337 Clinical Trial. - Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J. Valcárcel D, et al. J Clin Oncol. 2008 Feb 1;26(4):577-84. doi: 10.1200/JCO.2007.11.1641. Epub 2007 Dec 17. J Clin Oncol. 2008. PMID: 18086801 - Allogeneic stem cell transplantation after reduced-intensity conditioning for acute myeloid leukaemia: impact of chronic graft-versus-host disease.
Valcárcel D, Martino R, Piñana JL, Sierra J. Valcárcel D, et al. Curr Opin Oncol. 2009 Jun;21 Suppl 1:S35-7. doi: 10.1097/01.cco.0000357474.66035.9b. Curr Opin Oncol. 2009. PMID: 19561412 Review.
Cited by
- Impact of extramedullary disease in AML patients undergoing sequential RIC for HLA-matched transplantation: occurrence, risk factors, relapse patterns, and outcome.
Fraccaroli A, Vogt D, Rothmayer M, Spiekermann K, Pastore F, Tischer J. Fraccaroli A, et al. Ann Hematol. 2023 Aug;102(8):2213-2223. doi: 10.1007/s00277-023-05281-8. Epub 2023 Jun 10. Ann Hematol. 2023. PMID: 37300568 Free PMC article. - The Hematology of Tomorrow Is Here-Preclinical Models Are Not: Cell Therapy for Hematological Malignancies.
Arranz L. Arranz L. Cancers (Basel). 2022 Jan 24;14(3):580. doi: 10.3390/cancers14030580. Cancers (Basel). 2022. PMID: 35158848 Free PMC article. Review. - Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.
Pingali SR, Champlin RE. Pingali SR, et al. Bone Marrow Transplant. 2015 Sep;50(9):1157-67. doi: 10.1038/bmt.2015.61. Epub 2015 May 18. Bone Marrow Transplant. 2015. PMID: 25985053 Free PMC article. Review. - Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study.
Nikolousis E, Nagra S, Pearce R, Perry J, Kirkland K, Byrne J, Dignan F, Tholouli E, Gilleece M, Russell N, Littlewood T, Cook M, Peniket A, Shaw BE, Cook G, Craddock C. Nikolousis E, et al. Bone Marrow Transplant. 2015 Jan;50(1):82-6. doi: 10.1038/bmt.2014.215. Epub 2014 Oct 6. Bone Marrow Transplant. 2015. PMID: 25285801 - Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies.
Oudin C, Chevallier P, Furst S, Guillaume T, El Cheikh J, Delaunay J, Castagna L, Faucher C, Granata A, Devillier R, Chabannon C, Esterni B, Vey N, Mohty M, Blaise D. Oudin C, et al. Haematologica. 2014 Nov;99(11):1762-8. doi: 10.3324/haematol.2014.105981. Epub 2014 Aug 1. Haematologica. 2014. PMID: 25085356 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical